The company agreed to the protocol because the FDA has final authority. If they didn’t agree to the protocol, there would’ve been no trial. There is ample proof that the company believed 4 doses was the appropriate dosing and wanted to do the trial that way, but for some mysterious reason the FDA pulled rank and insisted on only 2.